Live Breaking News & Updates on Director Redmile Group
Stay updated with breaking news from Director redmile group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Fate Therapeutics (NASDAQ:FATE – Get Rating) had its price objective cut by Stifel Nicolaus from $5.30 to $5.00 in a report issued on Thursday morning, The Fly reports. Other analysts also recently issued reports about the stock. HC Wainwright downgraded shares of Fate Therapeutics from a buy rating to a neutral rating and reduced their […] ....
Fate Therapeutics (NASDAQ:FATE – Get Rating) had its price target trimmed by Cantor Fitzgerald from $8.00 to $5.00 in a research report report published on Thursday, The Fly reports. Several other brokerages have also issued reports on FATE. Morgan Stanley cut their price target on Fate Therapeutics from $35.00 to $8.00 and set an equal […] ....
Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) – Research analysts at SVB Leerink issued their Q4 2024 earnings per share estimates for Fate Therapeutics in a research report issued on Thursday, May 4th. SVB Leerink analyst D. Graybosch anticipates that the biopharmaceutical company will post earnings of ($0.45) per share for the quarter. SVB Leerink […] ....
Fate Therapeutics (NASDAQ:FATE – Get Rating) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.36, Briefing.com reports. Fate Therapeutics had a negative return on equity of 50.86% and a negative net margin of 292.55%. The firm had […] ....
Fate Therapeutics (NASDAQ:FATE – Get Rating) released its earnings results on Wednesday. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.36, Briefing.com reports. The firm had revenue of $58.98 million during the quarter, compared to the consensus estimate of $33.53 million. Fate Therapeutics had a […] ....